112.58
price up icon0.63%   0.71
after-market Handel nachbörslich: 112.39 -0.19 -0.17%
loading
Schlusskurs vom Vortag:
$111.87
Offen:
$111.5
24-Stunden-Volumen:
1.11M
Relative Volume:
0.49
Marktkapitalisierung:
$237.82B
Einnahmen:
$53.22B
Nettoeinkommen (Verlust:
$12.86B
KGV:
17.62
EPS:
6.39
Netto-Cashflow:
$14.85B
1W Leistung:
+0.07%
1M Leistung:
-0.77%
6M Leistung:
+6.44%
1J Leistung:
+13.31%
1-Tages-Spanne:
Value
$111.06
$112.58
1-Wochen-Bereich:
Value
$111.06
$113.91
52-Wochen-Spanne:
Value
$96.06
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Firmenname
Novartis Ag Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
75,883
Name
Twitter
@novartis
Name
Nächster Verdiensttermin
2025-01-31
Name
Neueste SEC-Einreichungen
Name
NVS's Discussions on Twitter

Vergleichen Sie NVS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.58 222.20B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
LLY
Lilly Eli Co
722.57 642.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.58 367.19B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.62 322.44B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.46 302.90B 43.59B 15.04B 10.74B 3.3766

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Herabstufung UBS Buy → Neutral
2025-02-12 Eingeleitet Morgan Stanley Underweight
2025-02-04 Hochstufung Deutsche Bank Hold → Buy
2024-12-04 Herabstufung HSBC Securities Hold → Reduce
2024-09-11 Herabstufung BofA Securities Buy → Neutral
2024-09-05 Herabstufung Goldman Buy → Neutral
2024-09-03 Herabstufung Jefferies Buy → Hold
2024-07-19 Herabstufung Deutsche Bank Buy → Hold
2024-05-30 Eingeleitet Goldman Buy
2024-02-23 Eingeleitet BMO Capital Markets Market Perform
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-18 Herabstufung HSBC Securities Buy → Hold
2023-09-25 Hochstufung Morgan Stanley Underweight → Equal-Weight
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-26 Hochstufung Deutsche Bank Hold → Buy
2023-03-27 Hochstufung Deutsche Bank Sell → Hold
2023-01-26 Herabstufung Citigroup Buy → Neutral
2022-12-05 Hochstufung Stifel Hold → Buy
2022-09-15 Herabstufung Credit Suisse Neutral → Underperform
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-05-09 Herabstufung Wolfe Research Outperform → Peer Perform
2022-01-10 Fortgesetzt Citigroup Buy
2021-12-14 Herabstufung Redburn Buy → Neutral
2021-12-06 Herabstufung Exane BNP Paribas Outperform → Neutral
2021-12-03 Herabstufung Bryan Garnier Buy → Neutral
2021-09-20 Herabstufung Deutsche Bank Hold → Sell
2021-03-22 Eingeleitet Bernstein Mkt Perform
2021-03-10 Herabstufung Argus Buy → Hold
2021-02-01 Herabstufung Cowen Outperform → Market Perform
2021-01-15 Eingeleitet Deutsche Bank Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-09-10 Hochstufung UBS Neutral → Buy
2020-09-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-15 Hochstufung Citigroup Neutral → Buy
2020-03-10 Hochstufung Morgan Stanley Underweight → Equal-Weight
2020-02-25 Herabstufung Guggenheim Buy → Neutral
2019-04-25 Hochstufung Guggenheim Neutral → Buy
2019-04-25 Hochstufung Liberum Hold → Buy
2019-04-10 Herabstufung Morgan Stanley Equal-Weight → Underweight
2019-01-02 Herabstufung JP Morgan Neutral → Underweight
2018-12-11 Fortgesetzt Jefferies Buy
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Underperform → Buy
2018-05-29 Herabstufung HSBC Securities Buy → Hold
2018-05-25 Hochstufung Credit Suisse Underperform → Neutral
2018-01-25 Bestätigt Leerink Partners Outperform
2017-12-06 Herabstufung BofA/Merrill Neutral → Underperform
2017-07-26 Hochstufung Morgan Stanley Underweight → Overweight
2017-07-05 Herabstufung Credit Suisse Neutral → Underperform
2017-03-09 Eingeleitet Liberum Buy
Alle ansehen

Novartis Ag Adr Aktie (NVS) Neueste Nachrichten

pulisher
01:00 AM

Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
10:58 AM

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

10:58 AM
pulisher
May 28, 2025

Why Value Investing Has Worked Better Outside the US - Morningstar

May 28, 2025
pulisher
May 22, 2025

Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com

May 22, 2025
pulisher
May 19, 2025

Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement

May 19, 2025
pulisher
May 15, 2025

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com

May 14, 2025
pulisher
May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025
pulisher
Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025
pulisher
Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025
pulisher
Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025
pulisher
Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025
pulisher
Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025
pulisher
Apr 11, 2025

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ

Apr 11, 2025
pulisher
Apr 11, 2025

Pharma Stock Roundup: EU Nod To Expanded Use Of ABBV, AZN Drugs & More - Barchart.com

Apr 11, 2025
pulisher
Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025
pulisher
Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025
pulisher
Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025
pulisher
Mar 26, 2025

No room on the ARK? - Morningstar

Mar 26, 2025
pulisher
Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025
pulisher
Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025
pulisher
Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025
pulisher
Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025
pulisher
Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025
pulisher
Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025
pulisher
Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025
pulisher
Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025
pulisher
Mar 07, 2025

Elizabeth McNally, M.D., Ph.D. - Novartis

Mar 07, 2025
pulisher
Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025

Finanzdaten der Novartis Ag Adr-Aktie (NVS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general NVO
$69.46
price up icon 1.25%
drug_manufacturers_general MRK
$76.40
price up icon 0.30%
drug_manufacturers_general GSK
$40.00
price up icon 2.09%
$283.54
price up icon 1.85%
$185.62
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):